|
Jul 26
|
Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop
|
|
Jul 25
|
Assembly Bio’s (ASMB) HBV Drug Shows Strong Efficacy in Phase 1b Trial
|
|
Jul 1
|
First subject dosed in Assembly Biosciences’ study for genital herpes
|
|
Jun 30
|
Assembly Biosciences Says First Participant Dosed in Phase 1b Study of HSV Drug ABI-1179
|
|
Jun 30
|
Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179
|
|
Jun 25
|
Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B
|
|
May 27
|
Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference
|
|
Apr 9
|
Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress
|
|
Apr 8
|
Down -22.6% in 4 Weeks, Here's Why Assembly Biosciences (ASMB) Looks Ripe for a Turnaround
|
|
Feb 20
|
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes
|
|
Oct 2
|
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?
|
|
Aug 30
|
Is Sensus Healthcare (SRTS) Stock Outpacing Its Medical Peers This Year?
|
|
Aug 29
|
Individual investors in Assembly Biosciences, Inc. (NASDAQ:ASMB) are its biggest bettors, and their bets paid off as stock gained 14% last week
|
|
Aug 8
|
Assembly Biosciences: Q2 Earnings Snapshot
|
|
Aug 8
|
Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates
|
|
Jul 19
|
Investors in Assembly Biosciences (NASDAQ:ASMB) have unfortunately lost 90% over the last five years
|
|
Jun 18
|
Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection
|
|
Jun 17
|
Assembly Biosciences Announces $12.6 Million in Equity Financings
|
|
Jun 10
|
Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366
|
|
Jun 5
|
Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress™ 2024
|